How to relax your pelvic floor muscles
Are you paying attention to your pelvic floor health?
The pelvic floor is a group of muscles and nerves that form a "supportive hammock" from the back, through the tailbone, lower abdominal area and hips, gynecologist and urologist Sonia Bahlani, M.D., tells USA TODAY. Together, this dictates urinary and fecal patterns, sexual function and even how you sit.
"People never think of the pelvic floor as this powerhouse of the body, but it truly is," Dr. Bahlani says.
A common misconception about the pelvic floor, Dr. Bahlani highlights, is thinking that the opposite of a tight pelvic floor is a weak pelvic floor.
"People think of a tight pelvic floor as a strong pelvic floor. But a tight pelvic floor, in fact, is a weak pelvic floor," she says. They're two sides of the same coin: Both cause similar issues, but the way they're treated usually differs.
Need a break? Play the USA TODAY Daily Crossword Puzzle.
Another misconception: that pelvic floor issues are only a concern for people who have vaginas. They actually impact everyone, regardless of their anatomy, Dr. Bahlani notes.
Here's what health experts want you to know about identifying a tight pelvic floor, and how best to fix one.
'Take care of your pelvic floor'Brittany Mahomes speaks out after injury
How do you know if your pelvic floor is tight?
Roughly a third of women and 16% of men will experience some kind of pelvic floor disorder in their lifetime, statistics have shown.
A tight pelvic floor is what happens when the muscles are in a constant state of contraction, according to the Cleveland Clinic. This leads to issues including urinary or fecal incontinence, painful sex or pelvic organ prolapse, which is when "you can actually feel the uterus come through the vagina," Dr. Bahlani says.
If you're struggling with those issues, a doctor may test your pelvic floor strength with a biofeedback machine, Dr. Bahlani says. "They'll say, 'contract your pelvic floor muscles, so act like you're pushing stool out or act like you're peeing,'" she says. "And they can measure how strong the pelvic floor is."
How to relax pelvic floor muscles
You've likely heard of Kegels: the exercise where you contract muscles as if you're trying to avoid passing gas, pretending to tighten the vagina around a tampon or stopping your urine stream, according to Harvard Health.
It's the best-known way to strengthen the pelvic floor, but it may not actually be the best one for you.
Many women experience pain with sex.Is pelvic floor therapy the answer not enough people are talking about?
"Kegels only work for a subset of patients whose weak pelvic floor is due to laxity of the muscles, as opposed to tightness of the muscles," Dr. Bahlani says. She only advises about 20% of her patients to use Kegels alone; others are better suited with physical therapy, yoga poses, bird dog and core strengthening exercises.
"Kegels only work for a subset of patients whose weak pelvic floor is due to laxity of the muscles, as opposed to tightness of the muscle," Dr. Bahlani says. In other words, kegels could be helpful if your pelvic floor is weak, but tight pelvic floors are better treated through tactics such as yoga, meditation and other relaxing techniques.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
an hour ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
Yahoo
10 hours ago
- Yahoo
‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge
The parents of a 19-year-old who dreamed of fame and died after trying the TikTok 'dusting' trend are warning others about its deadly risks. Renna O'Rourke and her boyfriend DoorDashed aerosol keyboard cleaner to her parents' Tempe, Arizona, home without her mother's knowledge, Dana O'Rourke told 12 News. The dusting trend, also known as chroming or huffing, involves inhaling common household cleaners to get high for views online. The sensation causes brief euphoria but can cause instant, fatal damage, often due to heart failure, according to the Cleveland Clinic. After inhaling the keyboard cleaner, Renna went into cardiac arrest, spent a week unconscious in the intensive care unit, and then was declared brain-dead. Renna's parents described their late daughter as 'vivacious and caring and loyal.' Her father, Aaron O'Rourke, told 12 News that Renna loved to sing and lit up every room with her smile and laughter. 'She always said, 'I'm going to be famous, dad. Just you watch. I'm going to be famous,' and unfortunately, this is not under the most optimal of circumstances,' Aaron O'Rourke, told the outlet.. Despite the less-than-ideal circumstances, the O'Rourke family is now working to honor Renna by spreading the word about the dangers of huffing for teens and parents. 'There's no ID required. It's odorless. It's everything kids look for. They can afford it, they can get it, and it doesn't show in mom and dad's drug test,' Dana O'Rourke told AZ Family about access to the trendy chemicals. She added, 'Don't take your kid's word for it. Dig deep. Search their rooms. Don't trust — and that sounds horrible, but it could save their life.' A GoFundMe started to help the O'Rourke family with hospital bills, burial and therapy costs, and to spread awareness about huffing has surpassed its $5,000 goal and sits at over $9,000 at the time of publication.
USA Today
a day ago
- USA Today
Emmy Award-winning actress on mission to show family caregivers they aren't alone
Emmy Award-winning actress on mission to show family caregivers they aren't alone Award-winning actress Uzo Aduba narrates the PBS documentary "Caregiving," which premieres June 24 at 9 p.m. EST. Show Caption Hide Caption Hulu's 'The Supremes at Earl's All-You-Can-Eat' tracks three best pals Aunjanue Ellis-Taylor, Sanaa Lathan and Uzo Aduba star as a trio of best friends in the Hulu drama "The Supremes at Earl's All-You-Can-Eat." Emmy Award-winning actress Uzo Aduba cared for her mom, who was diagnosed with pancreatic cancer in 2019, for 495 days. But for a while, Aduba never considered herself a caregiver. 'One day our mother was fine, and then one day she wasn't," Aduba told USA TODAY. "So in the middle of 'wasn't,' you're just trying to figure out how to assemble the pieces to keep life as quote-unquote 'normal' as possible.' More: The caregiving crisis is real. USA TODAY wants to hear from you about how to solve it. Aduba said she always associated the term "caregiver" with medical staff. Now, she knows there are millions of caregivers across the country with no medical training, who − like her − were thrust into caregiving roles without warning once their loved one got sick. 'I didn't realize that there was this whole framework, frankly, of loved ones who were serving in this sort of invisible labor, all across the country, day in, day out, in varying ways, as caregivers to people," she said. Now, she wants other family caregivers to know they aren't alone. Aduba, known for her roles in the television series "Orange Is the New Black" and "The Residence," narrates the PBS documentary "Caregiving," which premieres June 24 at 9 p.m. EST. The film was created with executive producer and Academy Award-nominated actor Bradley Cooper and features caregivers from across the country. 'It was the reading of the stories, of the history of it, the families, the individuals involved in caregiving, the advocates for it that drew me to it because I saw a lot of myself in the portraiture," Aduba said of the film. "I belong to the caregiving community." The need for care is universal, said Ai-jen Poo, executive director and board secretary for Caring Across Generations. She hopes having celebrities like Aduba and Cooper speak out about their caregiving experience will help people see how caregiving connects us all. More: A caregiver dad, Bradley Cooper and how a national crisis inspired an unexpected film 'It is a reminder that every single one of us is touched by the need for care,' she said. 'As I write this, my mother is dying.' Uzo Aduba shares caregiving story in memoir released last year Aduba shared some of her caregiving experience in her book, "The Road is Good," which was released in September 2024. The sweeping memoir tells her story of growing up in a Nigerian immigrant family in Massachusetts. But Aduba's life story, as she notes in the book, is also the story of her relationship with her mother. There's no way to separate the two narratives. She starts the book with: "As I write this, my mother is dying." Aduba wrote of the range of emotions that came once her mother was diagnosed with pancreatic cancer: fear, anxiety, frustration and grief. She wrote of the the ups and downs of those 495 days, which collided with the COVID-19 pandemic, her engagement, and wedding. She also wrote of the duller moments of care that other family caregivers can relate to. "We took naps and watched whatever we could find on TV. We ordered takeout from the fancy steakhouse in town. We waited, stared at our phones, and took turns curling up with our mother in the hospital bed," she wrote in the book. Aduba said she and her sisters took shifts in caring for their mother. Later, when her mother went into hospice, Aduba described the hospice nurse as an angel. In her culture, Aduba explained, caregiving is "the greatest show of love." Aduba's time with her mother was priceless: 'I would do it again.' Another caregiver featured in the documentary, Matthew Cauli, is outspoken on social media about how difficult it is for caregivers to access resources. "I had to quit my job to go into poverty in order to get on Medicaid so that my wife could get some treatment," Cauli, who cares for his sick wife and young son, said in a recent social media post. "I've been in poverty for five years, credit card debt for five years. And I am stuck, I'm stuck, I'm stuck." In working on the film, Aduba said she learned a lot about how massive the caregiving crisis is. When she was a caregiver for her mom, she said, she didn't realize that resources were out there at all. 'We had no knowledge that that even existed, you know?' Aduba said. More: Chronic illness can be hard on marriage. Studies show it's worse when the wife is sick. There are a lot of family caregivers out there who don't know where to get resources, or that help exists, or about the policies advocates are trying to enact to bring more relief to caregivers. Aduba said the film does a great job at shining a light on the history of caregiving and advocacy work happening now to make things better. Aduba and her sisters didn't have time to think about anything else while they were caring for their mother, Aduba told USA TODAY. When you care for someone, she said, "your needs are second" to the patient. Her own health needs took a back seat during that time, her sleep schedule turned upside down and her free time ceased to exist. 'I would do it again," she said. "But I also know that I'm speaking from a place of immense privilege and not everybody... there are other people who are carrying way more than I on their day to day while also having to navigate caregiving at the same time.' Madeline Mitchell's role covering women and the caregiving economy at USA TODAY is supported by a partnership with Pivotal Ventures and Journalism Funding Partners. Funders do not provide editorial input. Reach Madeline at memitchell@ and @maddiemitch_ on X.
